user

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

被引：229
|
作者：
Verheijen, Remy B. [1 ]
Yu, Huixin [1 ]
Schellens, Jan H. M. [2 ,3 ]
Beijnen, Jos H. [1 ,3 ]
Steeghs, Neeltje [2 ]
Huitema, Alwin D. R. [1 ,4 ]
机构：
[1] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Pharm & Pharmacol, Amsterdam, Netherlands
[2] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Med Oncol & Clin Pharmacol, Amsterdam, Netherlands
[3] Univ Utrecht, Dept Pharmaceut Sci, Utrecht, Netherlands
[4] Univ Utrecht, Med Ctr, Dept Clin Pharm, Utrecht, Netherlands
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 05期
关键词：
CHRONIC MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; EXPOSURE-RESPONSE ANALYSIS; IMATINIB PLASMA-LEVELS; PHASE-I SAFETY; CLINICAL-RESPONSE; JAPANESE PATIENTS; CANCER-PATIENTS; POPULATION PHARMACOKINETICS; DOSE-ESCALATION;
D O I：
10.1002/cpt.787
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.
引用
收藏
页码：765 / 776
页数：12
相关论文
共 50 条
  • [21] Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
    Puisset, Florent
    Mseddi, Mourad
    Mourey, Loic
    Pouessel, Damien
    Blanchet, Benoit
    Chatelut, Etienne
    Chevreau, Christine
    CANCERS, 2023, 15 (01)
  • [22] SUSTAINED-RELEASE THEOPHYLLINE PREPARATIONS - PRACTICAL RECOMMENDATIONS FOR PRESCRIBING AND THERAPEUTIC DRUG-MONITORING
    GLYNNBARNHART, A
    HILL, M
    SZEFLER, SJ
    DRUGS, 1988, 35 (06) : 711 - 726
  • [23] Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations
    Hertz, Daniel L.
    Joerger, Markus
    Bang, Yung-Jue
    Mathijssen, Ron H.
    Zhou, Caicun
    Zhang, Li
    Gandara, David
    Stahl, Michael
    Monk, Bradley J.
    Jaehde, Ulrich
    Beumer, Jan H.
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [24] Therapeutic Drug Monitoring: The Need for Practical Guidance
    Alffenaar, Jan-Willem C.
    Heysell, Scott K.
    Mpagama, Stellah G.
    CLINICAL INFECTIOUS DISEASES, 2019, 68 (06) : 1065 - 1066
  • [25] Practical information for therapeutic drug monitoring of vancomycine
    Lefeuvre, Sandrine
    Bois-Maublanc, Julie
    Guilhaumou, Romain
    THERAPIE, 2020, 75 (05): : 506 - 509
  • [26] Novel Therapeutic Options with Continuous Glucose Monitoring - Practical Recommendations
    Seufert, Jochen
    Deiss, Dorothee
    Goelz, Stefan
    Haak, Thomas
    Klausmann, Gerhard
    Kroeger, Jens
    Lobmann, Ralf
    Pfeiffer, Andreas F. H.
    Schnell, Oliver
    Seibold, Alexander
    Siegmund, Thorsten
    Ziegler, Ralph
    DIABETOLOGIE UND STOFFWECHSEL, 2019, 14 (05) : 388 - 398
  • [27] Therapeutic drug monitoring in oncology: does it have a future?
    McMahon, Gillian
    O'Connor, Robert
    BIOANALYSIS, 2009, 1 (03) : 507 - 511
  • [28] A review of vancomycin therapeutic drug monitoring recommendations in Scotland
    Helgason, Kristjan O.
    Thomson, Alison H.
    Ferguson, Craig
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (06) : 1398 - 1399
  • [29] Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives
    Falkowski, Sabrina
    Woillard, Jean-Baptiste
    THERAPEUTIC DRUG MONITORING, 2019, 41 (05) : 568 - 574
  • [30] Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients
    Aquino, Maria
    Tinoco, Maria
    Bicker, Joana
    Falcao, Amilcar
    Rocha, Marilia
    Fortuna, Ana
    ANTIBIOTICS-BASEL, 2023, 12 (02):
12345